Zoetis Inc (NYSE:ZTS) – Investment analysts at Cantor Fitzgerald boosted their FY2018 earnings per share estimates for shares of Zoetis in a note issued to investors on Friday, according to Zacks Investment Research. Cantor Fitzgerald analyst L. Chen now forecasts that the company will earn $2.96 per share for the year, up from their previous forecast of $2.69. Cantor Fitzgerald has a “Buy” rating and a $90.00 price objective on the stock.
Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 15th. The company reported $0.69 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.03. The firm had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.40 billion. Zoetis had a return on equity of 65.96% and a net margin of 16.28%. Zoetis’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.47 EPS.
Shares of Zoetis (NYSE:ZTS) traded down $0.24 during trading hours on Monday, reaching $84.35. The company’s stock had a trading volume of 1,794,705 shares, compared to its average volume of 3,050,000. The firm has a market cap of $41,100.00, a PE ratio of 38.69, a PEG ratio of 1.89 and a beta of 0.97. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77. Zoetis has a 52-week low of $52.25 and a 52-week high of $85.54.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be paid a dividend of $0.126 per share. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date of this dividend is Thursday, April 19th. Zoetis’s dividend payout ratio is presently 22.94%.
In related news, insider Heidi C. Chen sold 37,453 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total value of $3,034,442.06. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Roxanne Lagano sold 35,663 shares of the stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $81.02, for a total value of $2,889,416.26. Following the completion of the transaction, the executive vice president now directly owns 49,919 shares in the company, valued at $4,044,437.38. The disclosure for this sale can be found here. In the last three months, insiders have sold 105,569 shares of company stock worth $8,594,429. Corporate insiders own 0.31% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Chemical Bank purchased a new position in shares of Zoetis in the 4th quarter worth $350,000. Cambridge Investment Research Advisors Inc. raised its position in Zoetis by 27.9% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 17,881 shares of the company’s stock valued at $1,288,000 after purchasing an additional 3,904 shares during the period. Xact Kapitalforvaltning AB raised its position in Zoetis by 9.8% in the fourth quarter. Xact Kapitalforvaltning AB now owns 70,114 shares of the company’s stock valued at $5,051,000 after purchasing an additional 6,253 shares during the period. Envestnet Asset Management Inc. raised its position in Zoetis by 31.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 134,904 shares of the company’s stock valued at $9,719,000 after purchasing an additional 32,149 shares during the period. Finally, Dixon Hubard Feinour & Brown Inc. VA raised its position in Zoetis by 106.2% in the fourth quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 25,090 shares of the company’s stock valued at $1,807,000 after purchasing an additional 12,925 shares during the period. 92.45% of the stock is currently owned by institutional investors and hedge funds.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.